NICE is the only major agency that makes an explicit cost-effectiveness threshold the centre of the decision. That changes what “evidence” means: the pivotal trial matters, but the economic model built on it is what gets appraised, and what gets negotiated.
The odds, from 521 novel EMA authorisations 2011–2020
The gap between positive and dispensed is nearly zero: a NICE yes is funded by statute. Posterior means with 90% credible intervals from our Bayesian pathway model; segment-level odds by technology, disease area and first-in-class status are in the subscription.
The pathway, step by step
Regulatory approval: the MHRA
Post-Brexit, the MHRA licenses independently, with international-recognition routes that lean on EMA or FDA reviews. Licensing and appraisal are formally separate, but NICE scoping starts around regulatory submission, so the tracks run in parallel.
Engage: NICE scientific advice (fee-based) while phase III is still amendableScoping and invitation: NICE selects and frames
New active substances are routed to technology appraisal by default. Scoping fixes the decision problem: population, comparators (established NHS practice), subgroups. Companies that skip the submission get a terminated appraisal, which reads as a “no” to the NHS.
Our data: 164 of 922 appraisals ended terminatedCompany submission: the economic case
The submission is a full cost-utility model against NHS practice: EQ-5D utilities, NHS/PSS costs, lifetime horizon per the reference case. The working threshold remains £20,000-30,000 per QALY, with a severity modifier that can weight QALYs up to 1.7× for the most severe conditions, the successor to the old end-of-life premium.
Engage: an evidence-assessment group will interrogate every model assumption; pre-empt themCommittee, consultation, decision
An independent appraisal committee tests the model, hears consultees, and can consult on a draft negative before finalising. Most “yes” outcomes are optimised: a narrower population than the licence, or contingent on a confidential discount.
Our data: 92% of decided appraisals positive · 61% of positives restrictedCommercial deals and managed access
Where the price misses the threshold, NHS England's commercial team negotiates confidential patient-access discounts. Genuinely uncertain evidence can route into managed access (the Cancer Drugs Fund and Innovative Medicines Fund): funded data collection with a re-appraisal at the end, a detour rather than a destination.
Engage: NHS England commercial: the discount, not the list price,, is the real priceThe funding mandate, and the rebate
A positive TA obliges NHS commissioners to fund the medicine within 90 days, the strongest market-access guarantee in Europe. Sitting behind everything: the voluntary scheme (VPAG) claws back a sales levy whose headline rate is set annually. Build it into net revenue, not as a footnote.
Statutory: 90-day funding requirement post-TAWhat the record actually shows
Who decides what, and when to engage
| Institution | What it decides | Evidence it weighs | When to engage |
|---|---|---|---|
| MHRA Regulator | Licence and label | Efficacy, safety, quality | Scientific advice; international-recognition route planning |
| NICE HTA body | Whether the NHS should fund, and for whom | Cost per QALY vs NHS practice; EQ-5D utilities; severity modifier eligibility | Scientific advice pre-phase III; scoping; full engagement through appraisal |
| NHS England Payer / commercial | Confidential discounts, managed-access deals, CDF/IMF entry | Budget impact, deliverability, data-collection feasibility | As soon as threshold risk is visible, before the committee forces it |
| DHSC / VPAG Pricing scheme | The annual sales levy on branded medicines | Scheme membership and sales | At forecast build; it is a net-revenue line, not a footnote |
| ICBs & trusts Local NHS | Formulary adoption and speed of uptake within the mandate | Local budget impact, pathway fit | Post-TA; drives the uptake curve, not access |
The evidence England actually asks for
A model, not just a trial. The submission lives or dies on a cost-utility model built to the NICE reference case: lifetime horizon, NHS costs, EQ-5D. Trial excellence with a weak model loses; a defensible model can carry moderate evidence.
NHS-relevant comparators. The comparator is established NHS practice, which may be an off-patent generic at pennies. Our pricing data shows what that means: England erodes post-LoE prices by 90%+ within a year, and your comparator may already be there.
Utilities and severity. EQ-5D-derived quality-of-life gains move the ICER more than most clinical endpoints; severity-modifier eligibility (QALY shortfall) can be the difference between £30k and £51k of headroom per QALY.
Uncertainty, quantified. Probabilistic sensitivity analysis is expected, and the committee prices in uncertainty: wide confidence intervals cost money or force managed access.
Where companies get hurt
Planning a UK launch?
We build NICE-reference-case models, severity-modifier analyses and threshold-aware pricing strategy, grounded in the same appraisal record you can check on this site. Fixed fees, senior-built.
Talk to us about the UK